Table 1.
Clinical and Demographic Data for the Final Study Cohort
|
Diabetic Clinic n = 104 (%) |
Primary Care n = 148 (%) |
P Value | ||
|---|---|---|---|---|
| Age* | 59.5 (52.0‐66.0) | 58.0 (45.5‐68.0) | 0.358 | |
| Male sex,† n (%) | 68 (65.4) | 69 (46.6) | 0.003 | |
| Caucasian ethnicity,† n (%) | 86 (82.7) | 112 (75.7) | 0.181 | |
| Metabolic syndrome,† n (%) | 99 (95.2) | 114 (77.0) | <0.001 | |
| Type 2 diabetes,‡ n (%) | 104 (100) | 104 (70.3) | <0.001 | |
| Body mass index* (kg/m2) | 36.0 (30.3‐41.7) | 32.3 (28.8‐37.5) | 0.004 | |
| Waist* (cm) | 123.0 (108.0‐134.0) | 111.0 (100.3‐126.0) | <0.001 | |
| BMI‡ categorized, n (%) | normal weight | 2 (2.0) | 9 (6.1) | 0.049 |
| overweight | 19 (18.3) | 40 (27.0) | ||
| class I obesity | 27 (26.0) | 45 (30.4) | ||
| class II obesity | 26 (25.0) | 29 (19.6) | ||
| ≥class III obesity | 30 (28.8) | 25 (16.9) | ||
| Serum liver enzymes* | ALT (IU/mL) | 30 (21‐42) | 34 (22‐62) | 0.015 |
| AST (IU/mL) | 21 (15‐31) | 25 (17‐40) | 0.009 | |
| GGT (IU/mL) | 28 (20‐50) | 36 (20‐68) | 0.061 | |
| Platelet count§ (×109) | 244 ± 62 | 249 ± 65 | 0.599 | |
| Serum albumin* (g/L) | 40 (38‐42) | 42 (40‐44) | 0.001 | |
| LSM range*,‖ | 2.6‐51.4 | 2.5‐63.9 | 0.300 | |
| LSM ≥8.2 kPa,†,‖ n (%) | 28 (31.1) | 44 (31.4) | 0.960 | |
| ELF test range* | 7.3‐13.0 | 6.6‐12.6 | 0.947 | |
| ELF ≥9.8,† n (%) | 27 (26.0) | 45 (30.4) | 0.442 | |
| NFS,‡ n (%) | low | 4 (3) | 44 (29.7) | <0.001 |
| indeterminate | 66 (63.5) | 74 (50.0) | ||
| high | 34 (32.7) | 30 (20.3) | ||
| FIB‐4 score,† n (%) | low | 61 (58.7) | 89 (60.1) | 0.972 |
| indeterminate | 38 (36.5) | 52 (35.1) | ||
| high | 5 (4.8) | 7 (4.7) | ||
*Continuous data presented (median [IQR]) analyzed using Mann‐Whitney U test; †categorical data presented analyzed using Pearson's chi‐squared test; ‡categorical data presented analyzed using Fisher's exact test; §continuous data presented (mean ± SD) analyzed using an independent t test; ‖LSM presented for the 230 patients with reliable LSM.